Melanoma

Showing NaN - NaN of 82

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)

Recruiting
  • Colorectal Carcinoma
  • +21 more
  • Dual X-ray Absorptiometry
  • +2 more
  • Birmingham, Alabama
  • +18 more
Jan 30, 2023

Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)

Active, not recruiting
  • Melanoma
  • +7 more
  • Scottsdale, Arizona
  • +36 more
Dec 22, 2022

Melanoma, NSCLC, Colorectal Cancer Trial in United States (LYL845)

Recruiting
  • Melanoma
  • +2 more
  • LYL845
  • Columbus, Ohio
  • +3 more
Dec 19, 2022

Melanoma Trial in Worldwide (Dabrafenib, Trametinib, Placebos)

Active, not recruiting
  • Melanoma
  • Birmingham, Alabama
  • +209 more
Nov 14, 2022

Melanoma Trial in Worldwide (Ceralasertib, Durvalumab)

Recruiting
  • Melanoma
  • Los Angeles, California
  • +75 more
Dec 5, 2022

Melanoma Trial in Worldwide (Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination)

Recruiting
  • Melanoma
  • Nivolumab
  • Nivolumab + Relatlimab Fixed Dose Combination
  • Birmingham, Alabama
  • +185 more
Dec 3, 2022

Melanoma, Breast Carcinoma, Hepatocellular Carcinoma Trial in United States (XmAb20717)

Completed
  • Melanoma
  • +27 more
  • XmAb20717
  • Los Angeles, California
  • +16 more
Nov 29, 2022

Melanoma Trial in Worldwide (Talimogene Laherparepvec, Pembrolizumab, Placebo)

Terminated
  • Melanoma
  • Talimogene Laherparepvec
  • +2 more
  • Birmingham, Alabama
  • +160 more
Nov 10, 2022

Melanoma Trial in Worldwide (Pembrolizumab, Placebo)

Active, not recruiting
  • Melanoma
  • Pembrolizumab
  • Placebo
  • Tucson, Arizona
  • +158 more
Oct 31, 2022

Advanced Cancer, Melanoma, NSCLC Trial in Worldwide (BMS-986205, Nivolumab, Ipilimumab)

Completed
  • Advanced Cancer
  • +2 more
  • Tucson, Arizona
  • +46 more
Aug 18, 2022

Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1429 more
Aug 17, 2022

Melanoma Trial in United States (CMP-001, Pembrolizumab)

Active, not recruiting
  • Melanoma
  • Phoenix, Arizona
  • +12 more
Aug 1, 2022

Melanoma, Advanced Melanoma, Metastatic Melanoma Trial in United States (CMP-001, Nivolumab)

Active, not recruiting
  • Melanoma
  • +3 more
  • Phoenix, Arizona
  • +24 more
Aug 1, 2022

Melanoma, Advanced Melanoma, Metastatic Melanoma Trial in United States (CMP-001, Nivolumab)

Active, not recruiting
  • Melanoma
  • +3 more
  • Phoenix, Arizona
  • +19 more
Aug 1, 2022

Melanoma, Solid Tumor Trial in Korea, Republic of, Spain, United States (DAY101, Pimasertib Hydrochloride)

Recruiting
  • Melanoma
  • Solid Tumor
  • Los Angeles, California
  • +13 more
Jul 27, 2022

Tumors, Colorectal Tumors, Melanoma Trial in United States (Alectinib)

Terminated
  • Neoplasms
  • +27 more
  • Culver City, California
  • +28 more
Jul 25, 2022

Oncology, Solid Tumor, Non Small Cell Lung Cancer Trial in United States (MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution

Active, not recruiting
  • Oncology
  • +5 more
  • MRx0518
  • Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
  • Kansas City, Kansas
  • +4 more
Jul 5, 2022

Oncology, Melanoma, Ovarian Cancer Trial in United States (E-602, Pembrolizumab)

Recruiting
  • Oncology
  • +16 more
  • E-602
  • Pembrolizumab
  • Grand Rapids, Michigan
  • +4 more
May 27, 2022

Sarcoma, Melanoma, Lung Cancer Trial in United States (PRT1419)

Recruiting
  • Sarcoma
  • +6 more
  • Denver, Colorado
  • +6 more
May 26, 2022

Unresectable And Metastatic Melanoma: The Optimize Study

Completed
  • Melanoma
    • Muscle Shoals, Alabama
    • +65 more
    May 17, 2022

    Cancer, Melanoma Trial in Worldwide (drug, biological, other)

    Recruiting
    • Cancer
    • Melanoma
    • Springdale, Arkansas
    • +70 more
    May 16, 2022

    Advanced Solid Tumor, NSCLC, Melanoma Trial in United States (AB308, Zimberelimab)

    Recruiting
    • Advanced Solid Tumor
    • +9 more
    • Phoenix, Arizona
    • +20 more
    May 2, 2022

    Melanoma, Non Small Cell Lung Cancer Trial in United States (VV1, Cemiplimab, Ipilumumab)

    Recruiting
    • Melanoma
    • Non Small Cell Lung Cancer
    • VV1
    • +2 more
    • Phoenix, Arizona
    • +22 more
    Apr 21, 2022

    Melanoma Patients Treated With IMLYGIC® to Characterize Risk of

    Recruiting
    • Melanoma
    • Herpetic Infection
      • Jefferson City, Missouri
      • +16 more
      Apr 11, 2022

      Melanoma Trial in Pittsburgh (Zimberelimab, Domvanalimab)

      Recruiting
      • Melanoma
      • Pittsburgh, Pennsylvania
        UPMC Hillman Cancer Center
      Apr 11, 2022